Elite’s
proprietary abuse-deterrent technology, ART™, is a multi-particulate
capsule which contains an opioid agonist in addition to naltrexone, an
opioid antagonist used primarily in the management of alcohol dependence
and opioid dependence. When this product is taken as intended, the
naltrexone is designed to pass through the body unreleased while the
opioid agonist releases over time providing therapeutic pain relief for
which it is prescribed. If the multi-particulate beads are crushed or
dissolved, the opioid antagonist, naltrexone, is designed to release.
The absorption of the naltrexone is intended to block the euphoria by
preferentially binding to same receptors in the brain as the opioid
agonist and thereby reducing the incentive for abuse or misuse by
recreational drug abusers. Elite’s pharmacological approach to
abuse-deterrence can be applied to a wide range of opioids used today in
pain management.
The question I have is this.....if methods of overdose is highest by route of oral consumption how does their ARC technology and multiparticulate design deter from misuse and abuse via oral consumer?
ReplyDeleteThe naltrexone is weak when consumed by swallowing. So if a person wants to take 10 pills to get high there is no deterrence of abuse via this route.
Or is there literature available from Phase 3 saying their deterrence is also for swallowing too?
Sorry auto corrected ART to say ARC. I meant ART
ReplyDeleteSorry auto corrected ART to say ARC. I meant ART
ReplyDelete